CORT · Corcept Therapeutics Incorporated

Summary

Corcept Therapeutics Incorporated announced on March 25, 2026, that the U.S. Food and Drug Administration approved Lifyorli™ (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who received one to three prior systemic treatment regimens, at least one including bevacizumab. Approval based on ROSELLA trial demonstrating 35% reduction in death risk and 30% reduction in progression risk.

Key takeaways

• FDA approved Lifyorli™ (relacorilant) + nab-paclitaxel on March 25, 2026
• Indication: platinum-resistant ovarian/fallopian tube/primary peritoneal cancer, 1-3 prior regimens including bevacizumab
• ROSELLA trial: 381 patients, 1:1 randomization, no biomarker required
• Overall survival: 16.0 months vs 11.9 months (HR 0.65, p=0.0004)
• PFS by BICR: HR 0.70, p=0.008
• First FDA-approved selective glucocorticoid receptor antagonist (SGRA)